Search

Displaying results 3881 - 3890 of 5897 in total
  1. Drug

    Resiquimod

    go.drugbank.com/drugs/DB06530
    Investigational

    It is also being studied to find out if adding it to a tumor vaccine improves the antitumor immune response. It is a type of imidazoquinoline and a type of immunomodulator. … When put on the skin, resiquimod causes some immune cells to make certain chemicals that may help them kill tumor cells.

  2. Drug

    5-fluorouridine

    go.drugbank.com/drugs/DB01629
    Investigational

    This compound belongs to the pyrimidine nucleosides and analogues. These are compounds comprising a pyrimidine base attached to a sugar. 5-fluorouridine is known to target uridine phosphorylase.

  3. Drug

    Upanovimab

    go.drugbank.com/drugs/DB16505
    Investigational

    Upanovimab (SCTA01) was under investigation in clinical trials (NCT04683328, NCT04644185, NCT04709328 and NCT05156645) to evaluate its safety and efficacy in patients with severe COVID-19

  4. Drug

    Cocamidopropyl betaine

    go.drugbank.com/drugs/DB11350
    Approved

    Impurities formed during the manufacturing process are thought to increase the prevalence of contact sensitization and mild skin irritations.

    Products: Balmers Hanryeoncho W
  5. Drug

    Quaternium-15

    go.drugbank.com/drugs/DB14198
    Approved

    Sensitivity to Quaternium-15 may be identified with a clinical patch test.

  6. Drug

    Clonidine

    go.drugbank.com/drugs/DB00575
    ApprovedInvestigational

    Clonidine is an imidazole derivate that acts as an agonist of alpha-2 adrenoceptors. This activity is useful for the treatment of hypertension, severe pain, and ADHD. Clonidine was granted FDA approval on 3 September 1974.

  7. Drug

    Sitamaquine

    go.drugbank.com/drugs/DB04909
    Investigational

    Sitamaquine (WR-6026) is an orally active 8-aminoquinoline analog in development by the Walter Reed Army Institute, in collaboration with GlaxoSmithKline (formerly SmithKline Beecham), for the potential

  8. Drug

    R673

    go.drugbank.com/drugs/DB05466
    Experimental

    of limbic system with respect to anxiety and depression. … The phase II program for treatment of depression and anxiety is ongoing in the US and EU.It is not clear how tachykinin antagonists exert their effect, but SP levels have been commonly linked to the functioning

  9. Drug

    AGS-005

    go.drugbank.com/drugs/DB05741
    Experimental

    AGS-005 is a personalized dendritic cell-based immunotherapy, with optimized immune response characteristics, that is designed to stimulate the patient's immune system to target and destroy the patient's

  10. Drug

    GO-203-2C

    go.drugbank.com/drugs/DB15008
    Investigational

    GO-203-2C is under investigation in clinical trial NCT02204085 (A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia).